UBS’s Aceragen Inc ACGN Stock Holding History

UBS’s Portfolio ACGN Stock Details ACGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$1K	Hold	4	–	–	﹤0.01%	10201
2014 Q2	$1K	Buy	+4	New	+$1.65K	﹤0.01%	10259

Other funds holding ACGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

UBS's ACGN Position: Q3 2014 in Review

UBS increased its Aceragen Inc (ACGN) stake by 238% in Q3 2014, buying an estimated $22.3K and bringing the position to 88 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #7571.

UBS first reported a position in ACGN in Q1 2014 and has held it in 3 quarters since. The position peaked at $713K in Q1 2014. 62 funds tracked by Wall St. Rank hold ACGN as of Q3 2014.

UBS held 88 shares of Aceragen Inc worth $28K as of Q3 2014.
UBS bought 62 Aceragen Inc shares in Q3 2014, an estimated $22.3K.
Aceragen Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7571 holding.
UBS first reported a position in Aceragen Inc in Q1 2014 and has held it in 3 quarters since.
UBS's Aceragen Inc position peaked at $713K in Q1 2014.
62 funds tracked by Wall St. Rank held Aceragen Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.